Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DOOO vs ABOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DOOO Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

DOOO Overall Winner 6-Pillar Tally: DOOO 5 – 1 ABOS Matrix Metrics: DOOO 9 – 1 ABOS

As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DOOO carries a Unified Composite Score of 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin), whereas ABOS carries 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DOOO vs ABOS
DOOO NASDAQ Head-to-Head Winner
BRP Inc. Common Subordinate Voting Shares
Miscellaneous Transportation Equipment
$76.20
+1.55% 1D
Market Cap $5.1B
TTM Revenue $7.75B
Forward P/E 14.4x
Beta / 30D Vol 0.97β · 39% Vol
Unified Composite Score
64.6 / 100 BUY
Tech 60.0 Fund 54.0 Flow 50.0 Mom 47.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 79
RSI-14: 79.2 · SMA20: $66.65 · SMA50: $65.66
ABOS NASDAQ
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.19
-3.52% 1D
Market Cap $14.0M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.62β · 326% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 45.0 Fund 58.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -37.5%), weak momentum, RSI 21
RSI-14: 21.4 · SMA20: $0.63 · SMA50: $1.57

6-Pillar Scorecard Institutional Category Breakdown (DOOO 5 – 1 ABOS)

Columns: Metric · DOOO · ABOS
1. Valuation Multiples DOOO
Forward P/E 14.4x N/M
Trailing P/E 36.1x N/M
PEG Ratio 2.04x N/M
EV / Revenue 0.7x N/M
2. Growth & Scale DOOO
Revenue Growth (YoY) +4.3% +0.0%
Earnings Growth (YoY) +295.8% +0.0%
TTM Revenue (USD) $7.75B $329,000
Market Cap $5.1B $14.0M
3. Profitability & Quality DOOO
Gross Margin 21.2% N/A
Operating Margin 4.8% 0.0%
Net Profit Margin -0.5% 0.0%
Return on Equity (ROE) 37.5% -162.7%
4. Balance Sheet & Cash Flow DOOO
Cash Generation (TTM) $843M EBITDA -$105M EBITDA
Cash Flow Margin 10.9% EBITDA Mgn N/A
Net Cash / Leverage $6.65 Book/Sh · 37.5% ROE $27M Net Cash
Dividend Yield 1.22% None (0.00%)
5. Options & Positioning ABOS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 42.8% (<1st %ile) 232.4% (41st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat DOOO
OpEx & R&D Intensity 16.4% of Rev ($1.27B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Miscellaneous Transportation Equipment Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DOOO (9) vs ABOS (1)
Institutional Metric DOOO ABOS Criterion Row Edge
Market Capitalization
Scale
$5.1B $14.0M Larger Scale DOOO
Trailing P/E Ratio
Valuation
36.1x N/M Lower Multiple DOOO
Forward P/E Ratio
Valuation
14.4x N/M Lower Multiple DOOO
Revenue Growth (YoY)
Growth
+4.3% +0.0% Higher Growth DOOO
Operating Margin (TTM)
Profitability
4.8% 0.0% Higher Margin DOOO
Net Profit Margin
Profitability
-0.5% 0.0% Higher Margin ABOS
Return on Equity (ROE)
Capital Efficiency
37.5% -162.7% Higher ROE DOOO
52-Week Range Position
Momentum
96% ($32–$78) 1% ($0–$4) Stronger Trend DOOO
Beta / 30D Volatility
Risk Regime
0.97β · 39% Vol 2.62β · 326% Vol Lower Realized Risk DOOO
Unified Institutional Score
Composite Signal
64.6 / 100 (BUY) 49.2 / 100 (HOLD) Higher Composite DOOO
Trailing 12M Revenue (USD)
Operating Scale
$7.75B $329,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.04x PEG · 0.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$843M EBITDA ($6.65 Book/Sh · 37.5% ROE) -$105M EBITDA ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABOS +2.83 pp
DOOO: +23.2% · ABOS: +26.03%
3M Horizon ABOS +2.83 pp
DOOO: +23.2% · ABOS: +26.03%
6M Horizon ABOS +2.83 pp
DOOO: +23.2% · ABOS: +26.03%
1Y Horizon ABOS +2.83 pp
DOOO: +23.2% · ABOS: +26.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DOOO vs ABOS. Trailing 12-month operating profitability (DOOO 4.8% vs ABOS 0.0%) and valuation multiples (DOOO 14.4x vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DOOO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.75B
Gross Margin21.2%
Op. Margin4.8%
ROE / Fwd P/E37.5% · 14.4x
ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DOOO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DOOO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DOOO Moat Profile High-Margin Pricing Power Moat
Miscellaneous Transportation Equipment Operator
Competes within the Miscellaneous Transportation Equipment value chain with $5.1B market capitalization and 4.8% operating margin.
OpEx & R&D Reinvestment 16.4% of Rev ($1.27B)
90D Engineering Disclosures 0 Published
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $14.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DOOO vs ABOS Key Questions & Quantitative Answers

As of Nov 20, 2026, BRP Inc. Common Subordinate Voting Shares (DOOO) is the stronger overall head-to-head candidate over Acumen Pharmaceuticals, Inc. (ABOS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DOOO carries a Unified Composite Score of 64.6/100 (BUY) at $76.20 (14.4x Forward P/E, 4.8% operating margin), whereas ABOS carries 49.2/100 (HOLD) at $0.19 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: DOOO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.2); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DOOO leads the Growth & Scale pillar: DOOO posts +4.3% YoY revenue growth and +295.8% YoY earnings growth on $7.75B TTM revenue (21.2% gross margin, 4.8% operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DOOO generates $7.75B in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, DOOO deploys 16.4% of Rev ($1.27B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.

DOOO screens cheaper on headline valuation multiples. DOOO trades at 14.4x Forward P/E, 36.1x Trailing P/E, 2.04x PEG, and 0.7x EV/Revenue (10.9% EBITDA margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DOOO (37.5% ROE) versus ABOS (-162.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DOOO carries 42.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 39% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.62β · 326% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.